These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32232111)

  • 21. The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes.
    Johansen NJ; Knop FK
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):311-317. PubMed ID: 36639124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.
    Saiz LC; Gorricho J; Garjón J; Celaya MC; Muruzábal L; Malón MDM; Montoya R; López A
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD010315. PubMed ID: 29020435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Implications of NLRP3-Mediated Inflammation in Coronary Artery Disease.
    Hemenway G; Frishman WH
    Cardiol Rev; 2022 Mar-Apr 01; 30(2):90-99. PubMed ID: 33883451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.
    Saiz LC; Gorricho J; Garjón J; Celaya MC; Erviti J; Leache L
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD010315. PubMed ID: 30027631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noncoding RNAs regulate NF-κB signaling to modulate blood vessel inflammation.
    Cheng HS; Njock MS; Khyzha N; Dang LT; Fish JE
    Front Genet; 2014; 5():422. PubMed ID: 25540650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Krüppel-Like Factors in Vascular Inflammation: Mechanistic Insights and Therapeutic Potential.
    Sweet DR; Fan L; Hsieh PN; Jain MK
    Front Cardiovasc Med; 2018; 5():6. PubMed ID: 29459900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander?
    Muhammad K; Ayoub MA; Iratni R
    Curr Pharm Des; 2021; 27(18):2141-2150. PubMed ID: 33461451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The brain-gut axis, inflammatory bowel disease and bioelectronic medicine.
    Eberhardson M; Levine YA; Tarnawski L; Olofsson PS
    Int Immunol; 2021 Jun; 33(6):349-356. PubMed ID: 33912906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Approaches Targeting Inflammation in Cardiovascular Disorders.
    Jones DP; Patel J
    Biology (Basel); 2018 Nov; 7(4):. PubMed ID: 30453474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Thuren T; Zalewski A; Libby P
    Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis.
    Hettwer J; Hinterdobler J; Miritsch B; Deutsch MA; Li X; Mauersberger C; Moggio A; Braster Q; Gram H; Robertson AAB; Cooper MA; Groß O; Krane M; Weber C; Koenig W; Soehnlein O; Adamstein NH; Ridker P; Schunkert H; Libby P; Kessler T; Sager HB
    Cardiovasc Res; 2022 Oct; 118(13):2778-2791. PubMed ID: 34718444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications.
    Montarello NJ; Nguyen MT; Wong DTL; Nicholls SJ; Psaltis PJ
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):347-362. PubMed ID: 33170943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis.
    Punch E; Klein J; Diaba-Nuhoho P; Morawietz H; Garelnabi M
    J Am Heart Assoc; 2022 Feb; 11(3):e023328. PubMed ID: 35048716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-inflammatory and immune-modulatory therapies for preventing atherosclerotic cardiovascular disease.
    Yamashita T; Sasaki N; Kasahara K; Hirata K
    J Cardiol; 2015 Jul; 66(1):1-8. PubMed ID: 25744783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in therapeutic targeting of inflammation in atherosclerosis.
    Hedin U; Matic LP
    J Vasc Surg; 2019 Mar; 69(3):944-951. PubMed ID: 30591299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the adaptive immune system: new strategies in the treatment of atherosclerosis.
    Zarzycka B; Nicolaes GA; Lutgens E
    Expert Rev Clin Pharmacol; 2015 May; 8(3):297-313. PubMed ID: 25843158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic targeting of chronic kidney disease-associated DAMPs differentially contributing to vascular pathology.
    Mazzarino M; Cetin E; Bartosova M; Marinovic I; Ipseiz N; Hughes TR; Schmitt CP; Ramji DP; Labéta MO; Raby AC
    Front Immunol; 2023; 14():1240679. PubMed ID: 37849759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases.
    Delbaere Q; Chapet N; Huet F; Delmas C; Mewton N; Prunier F; Angoulvant D; Roubille F
    Pharmaceuticals (Basel); 2023 Jan; 16(1):. PubMed ID: 36678575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokine Circuits in Cardiovascular Disease.
    Williams JW; Huang LH; Randolph GJ
    Immunity; 2019 Apr; 50(4):941-954. PubMed ID: 30995508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.